Conference Call with Torrent Pharmaceuticals Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Torrent Pharmaceuticals announced Q3FY26 results Total Income: Rs 3,303 crore against Rs 2,809 crore during Q3FY25, change 18%. India: Rs 1798 crore against Rs 1581 crore during Q3FY25, change 14%. United States: Rs 321 crore against Rs 271 crore during Q3FY25, change 18%. Germany: Rs 304 crore against Rs 282 crore during Q3FY25, change 8%. Brazil: Rs 371 crore against Rs 291 crore during Q3FY25, change 27%. Others: Rs 509 crore against Rs 384 crore during Q3FY25, change 33%. EBITDA: Rs 1,088 crore against Rs 914 crore during Q3FY25, change 19%. EBITDA Margin: 33% for Q3FY26. PAT: Rs 635 crore against Rs 503 crore during Q3FY25, change 26%. PAT Margin: 19% for Q3FY26. Result PDF